BioTech/Drugs - Newton, MA, US
Harbour Antibodies BV was established in 2006 to use transgenic mouse technology developed in the laboratory of Professor Frank Grosveld at Erasmus MC (Rotterdam, the Netherlands) for engineering mice to produce high affinity human antibodies. A fully owned subsidiary of Harbour BioMed, Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies:1) H2L2: Mice that generate antibodies comprised of two heavy chain and two light chains (H2L2) with fully human variable regions.2) HCAb: Mice that generate novel "heavy chain only" antibodies (HCAb). The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable drug-like properties.For additional information and Out-Licensing:Please visit http://harbourantibodies.com -or- email contact@harbourbiomed.com
Outlook
AddThis
WordPress.org
Mobile Friendly
Google Analytics